Sally Dewhurst
Direttore/Membro del Consiglio presso Grey Wolf Therapeutics Ltd.
Profilo
Sally Dewhurst is currently a Director at Grey Wolf Therapeutics Ltd., a Principal at Oxford Science Enterprises PLC, and a Board Member at Alethiomics Ltd.
Previously, she was a Board Observer at DJS Antibodies Ltd.
Ms. Dewhurst graduated from the University of Durham in 2011.
Posizioni attive di Sally Dewhurst
Società | Posizione | Inizio |
---|---|---|
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 24/01/2023 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investitore di Private Equity | 01/07/2023 |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby. | Direttore/Membro del Consiglio | 01/11/2022 |
Precedenti posizioni note di Sally Dewhurst
Società | Posizione | Fine |
---|---|---|
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Corporate Officer/Principal | 01/10/2022 |
Formazione di Sally Dewhurst
University of Durham | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby. | Commercial Services |
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Sally Dewhurst